# Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure

Study · id `cardio:ct-nct02556450` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02556450](<https://clinicaltrials.gov/study/NCT02556450>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02556450

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 528 participants.

## Technical summary

Registry record NCT02556450. Randomized; single masking; primary purpose other. Start 2016-01 (registry gives no type); primary completion 2018-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose other
- Phase: Phase 2
- Enrolled: 528 participants (enrolled count; ClinicalTrials.gov record NCT02556450, source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02556450, source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)
- Primary completion: 2018-09-30 (actual) (ClinicalTrials.gov record NCT02556450, source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)
- Completion: 2019-01-31 (actual) (ClinicalTrials.gov record NCT02556450, source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)
- Countries: France; Germany; Ireland; Italy; Netherlands; United Kingdom (ClinicalTrials.gov record NCT02556450, source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02556450-2022-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure
- Acronym: Homage
- Condition: Heart Failure
- Intervention (Drug): Spironolacton
- Lead sponsor: ACS Biomarker
- Lead sponsor class: OTHER
- Collaborator: Institut National de la Santé Et de la Recherche Médicale, France
- Collaborator class: OTHER\_GOV
- Collaborator: London School of Hygiene and Tropical Medicine
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: Institut National de la Santé Et de la Recherche Médicale, France (`cardio:org-institut-national-de-la-sante-et-de-la-recherche-medicale-3ba447`)
- Registry lists this organization as a collaborator: London School of Hygiene and Tropical Medicine (`cardio:org-london-school-of-hygiene-and-tropical-medicine`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF (`cardio:pubmed-33549556`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial (`cardio:pubmed-34372849`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial (`cardio:pubmed-34933097`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial (`cardio:pubmed-38729636`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 371dc8122c0d3c86389a1a96f803f1104f62828ada115b97f4aff9f1f1cf3bb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
